Cidara Therapeutics (CDTX) Misses Q1 EPS by 221c

Cidara Therapeutics (NASDAQ: CDTX) reported Q1 EPS of ($2.28), $2.21 worse than the analyst estimate of ($0.07). Revenue for the quarter came in at $8.46 million versus the consensus estimate of $13.05 million.

For earnings history and earnings-related data on Cidara Therapeutics (CDTX) click here.

You May Also Be Interested In

• onsemi downgraded by TD Cowen after Synaptics deal clouds growth story
• UBS Downgrades Grand Korea Leisure (114090:KS) to Neutral
• Apogee Enterprises (APOG) Tops Q1 EPS by 16c, Beats on Revenue; Offers FY27 Guidance